Volume | 151,010 |
|
|||||
News | - | ||||||
Day High | 1.40 | Low High |
|||||
Day Low | 1.31 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Biodesix Inc | BDSX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.33 | 1.31 | 1.40 | 1.40 | 1.31 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,062 | 151,010 | US$ 1.34 | US$ 202,106 | - | 1.03 - 2.21 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:11:29 | 1 | US$ 1.40 | USD |
Biodesix Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
135.72M | 96.94M | - | 49.09M | -52.15M | -0.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Biodesix News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BDSX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.24 | 1.40 | 1.21 | 1.26 | 31,466 | 0.16 | 12.90% |
1 Month | 1.27 | 1.52 | 1.15 | 1.35 | 241,641 | 0.13 | 10.24% |
3 Months | 1.98 | 2.03 | 1.15 | 1.43 | 139,507 | -0.58 | -29.29% |
6 Months | 1.47 | 2.21 | 1.15 | 1.61 | 121,513 | -0.07 | -4.76% |
1 Year | 1.68 | 2.21 | 1.03 | 1.55 | 98,039 | -0.28 | -16.67% |
3 Years | 16.28 | 16.4149 | 0.955 | 3.12 | 165,917 | -14.88 | -91.40% |
5 Years | 13.59 | 31.99 | 0.955 | 5.08 | 163,179 | -12.19 | -89.70% |
Biodesix Description
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |